iSpecimen Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
iSpecimen Inc. (ISPC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.15 per share for the 3-month period ending 2025-03-31, per its 10-Q filed 2026-05-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-05-18
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $2.15, a 10.42% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $2.40.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $1.77.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $7.30, a 31.13% decline from fiscal 2023.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $10.60, a 1294.74% increase from fiscal 2022.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $0.76, a 80.71% decline from fiscal 2021.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $3.94, a 616.36% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $2.15 10-Q · filed 2026-05-18 | ||||
| 2024-12-31 | $7.30 10-K · filed 2026-04-01 | ||||
| 2024-09-30 | $2.15 10-Q · filed 2025-11-17 | ||||
| 2024-06-30 | $2.60 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | $2.40 10-Q · filed 2025-05-19 | ||||
| 2023-12-31 | $10.60 10-K · filed 2025-04-14 | $0.53 10-K · filed 2024-03-13 | |||
| 2022-12-31 | $0.76 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $3.94 10-K/A · filed 2023-03-30 | ||||
| 2021-09-30 | $3.94 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $1.77 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $1.77 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | $0.55 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $0.72 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | $0.72 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |